UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature (London), 2021-09, Vol.597 (7878), p.732-737

2021

Volltextzugriff (PDF)

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature medicine, 2018-05, Vol.24 (5), p.638-646

2018

Volltextzugriff (PDF)

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Clinical cancer research, 2018-12, Vol.24 (24), p.6195-6203

2018

Volltextzugriff (PDF)

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Science translational medicine, 2020-09, Vol.12 (559)

2020

Volltextzugriff (PDF)

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Cancer cell, 2023-02, Vol.41 (2), p.340-355.e6

2023

Volltextzugriff (PDF)

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1

Cancer discovery, 2012-09, Vol.2 (9), p.798-811

2012

Volltextzugriff (PDF)

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (23), p.10794-10800

2005

Volltextzugriff (PDF)

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Clinical cancer research, 2009-05, Vol.15 (10), p.3484-3494

2009

Volltextzugriff (PDF)

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy

Clinical cancer research, 2014-07, Vol.20 (14), p.3849-3861

2014

Volltextzugriff (PDF)

Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

Clinical cancer research, 2023-01, Vol.29 (1), p.30-39

2023

Volltextzugriff (PDF)

Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism

The Journal of biological chemistry, 2007-10, Vol.282 (41), p.29919-29926

2007

Volltextzugriff (PDF)

β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers

Journal of neuroimmune pharmacology, 2020-03, Vol.15 (1), p.27-36

2020

Volltextzugriff (PDF)

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Clinical cancer research, 2023-04, Vol.29 (7), p.1292-1304

2023

Volltextzugriff (PDF)

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Cancer cell, 2021-09, Vol.39 (9), p.1178-1180

2021

Volltextzugriff (PDF)

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.439-451

2021

Volltextzugriff (PDF)

Expression and activity of src regulate interleukin-8 expression in pancreatic adenocarcinoma cells : Implications for angiogenesis

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7214-7222

2005

Volltextzugriff (PDF)

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Science translational medicine, 2017-11, Vol.9 (415)

2017

Volltextzugriff (PDF)

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1611-1623

2020

Volltextzugriff (PDF)

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

Clinical cancer research, 2005-07, Vol.11 (13), p.4923-4933

2005

Volltextzugriff (PDF)

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Cancer cell, 2024-02, Vol.42 (2), p.225-237.e5

2024

Volltextzugriff (PDF)

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature medicine, 2024-09, Vol.30 (9), p.2694-2695

2024

Volltextzugriff (PDF)

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer

Clinical cancer research, 2017-09, Vol.23 (18), p.5489-5501

2017

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(80)
Buchkapitel
(1)

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Humans
(36)
Oncology
(25)
Lung Neoplasms - Drug Therapy
(20)
Animals
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(17)
Cell Line, Tumor
(17)
Lung Neoplasms - Genetics
(17)
Mice
(16)
Carcinoma, Non-Small-Cell Lung - Genetics
(14)
Female
(13)
Mutation
(12)
Protein Kinase Inhibitors - Pharmacology
(11)
Biological And Medical Sciences
(10)
Cell Biology
(10)
Medical Sciences
(10)
Tumors
(10)
Erbb Receptors - Genetics
(9)
Male
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy

Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy

Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism

β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

Expression and activity of src regulate interleukin-8 expression in pancreatic adenocarcinoma cells : Implications for angiogenesis

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer

Suchergebnisse filtern